Overview of radiologic efficacy of new treatments.

ABSTRACT

Randomized, double-blind trials on new treatments, including anakinra, etanercept, infliximab, and leflunomide, show convincing reduction in radiographic progression. The relative efficacy of these new treatments is unknown. Head-to-head comparisons have not been performed and comparing treatment arms across trials has several pitfalls. These possible pitfalls are discussed.